Dimerix Bioscience Ltd - Профиль
Dimerix Ltd. is a clinical stage biopharmaceutical company, which engages in the development of new therapeutic treatments identified using its proprietary drug discovery platform, Receptor-Heteromer Investigation Technology. Its lead therapy DMX-200 focuses on 2 chronic kidney disease sub indications, Focal Segmental Glomerulosclerosis, and Diabetic Kidney Disease. The firm also has therapeutic candidates for the treatment of liver inflammation; ocular or otology diseases; and allergy or inflammation. The company was founded on May 13, 1975 and is headquartered in Melbourne, Australia.